Liquidia Corp
LQDA25.950USD
-0.140-0.54%
Close 08/15, 16:00（ET）Quotes delayed by 15 min
2.23BMarket Cap
LossP/E TTM
More Details of Liquidia Corp Company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Company Info
Ticker SymbolLQDA
Company nameLiquidia Corp
IPO dateJul 26, 2018
CEODr. Roger A. Jeffs, Ph.D.
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 26
Address419 Davis Drive
CityMORRISVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27560
Phone19193284400
Websitehttps://www.liquidia.com/
Ticker SymbolLQDA
IPO dateJul 26, 2018
CEODr. Roger A. Jeffs, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.12M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
368.64K
-1.09%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
262.60K
-1.62%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
214.39K
-0.78%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.37K
-0.34%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
110.59K
-21.34%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
18.40K
--
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.12M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
368.64K
-1.09%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
262.60K
-1.62%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
214.39K
-0.78%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.37K
-0.34%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
110.59K
-21.34%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
14.00M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: 20 hours ago
Updated: 20 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Caligan Partners, LP
9.43%
Farallon Capital Management, L.L.C.
7.94%
Manning (Paul B.)
7.16%
BlackRock Institutional Trust Company, N.A.
4.95%
The Vanguard Group, Inc.
4.16%
Other
66.36%
Shareholders
Shareholders
Proportion
Caligan Partners, LP
9.43%
Farallon Capital Management, L.L.C.
7.94%
Manning (Paul B.)
7.16%
BlackRock Institutional Trust Company, N.A.
4.95%
The Vanguard Group, Inc.
4.16%
Other
66.36%
Shareholder Types
Shareholders
Proportion
Hedge Fund
35.47%
Investment Advisor
16.61%
Investment Advisor/Hedge Fund
11.95%
Individual Investor
11.87%
Research Firm
3.52%
Corporation
2.69%
Private Equity
1.78%
Bank and Trust
0.41%
Pension Fund
0.22%
Other
15.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
350
67.92M
79.46%
-5.32M
2025Q1
356
67.75M
79.47%
-4.91M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
2023Q2
223
41.12M
63.56%
-6.16M
2023Q1
214
42.01M
65.00%
-5.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Caligan Partners, LP
8.12M
9.5%
--
--
Apr 23, 2025
Farallon Capital Management, L.L.C.
3.99M
4.67%
+700.00K
+21.27%
Mar 31, 2025
Manning (Paul B.)
6.16M
7.21%
+18.40K
+0.30%
Jun 17, 2025
BlackRock Institutional Trust Company, N.A.
4.20M
4.91%
+14.68K
+0.35%
Mar 31, 2025
The Vanguard Group, Inc.
3.45M
4.04%
-94.77K
-2.67%
Mar 31, 2025
Findell Capital Management LLC
2.89M
3.38%
-190.00K
-6.17%
Mar 31, 2025
Opaleye Management Inc.
2.26M
2.64%
+561.86K
+33.09%
Mar 31, 2025
Goldman Sachs & Company, Inc.
779.12K
0.91%
+70.88K
+10.01%
Mar 31, 2025
Jeffs (Roger A)
2.13M
2.49%
+38.56K
+1.85%
Jun 04, 2025
Legend Aggregator LP
1.86M
2.18%
-5.32M
-74.10%
Dec 31, 2024
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
2.16%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.34%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
iShares U.S. Pharmaceuticals ETF
0.44%
First Trust Small Cap Growth AlphaDEX Fund
0.19%
iShares Micro-Cap ETF
0.18%
SPDR S&P Kensho New Economies Composite ETF
0.16%
First Trust Small Cap Core Alphadex Fund
0.1%
iShares Russell 2000 Growth ETF
0.05%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
View more
SPDR S&P Pharmaceuticals ETF
Proportion2.16%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.34%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.78%
iShares U.S. Pharmaceuticals ETF
Proportion0.44%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.19%
iShares Micro-Cap ETF
Proportion0.18%
SPDR S&P Kensho New Economies Composite ETF
Proportion0.16%
First Trust Small Cap Core Alphadex Fund
Proportion0.1%
iShares Russell 2000 Growth ETF
Proportion0.05%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
